ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT01838174
Previous Study | Return to List | Next Study

A Trial of Neuroprotection With ACTH in Acute Optic Neuritis (ACTHAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01838174
Recruitment Status : Recruiting
First Posted : April 23, 2013
Last Update Posted : October 3, 2018
Sponsor:
Collaborators:
Mallinckrodt
University of Pennsylvania
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:

We hypothesize that the novel melanocortin-mediated anti-inflammatory effects of ACTH will reduce axonal loss following ON by limiting inflammatory optic nerve injury. We will compare the effect of ACTH and intravenous methylprednisolone therapy on axonal injury following ON using OCT, a sensitive, reproducible and noninvasive tool to measure RNFL thickness.

The primary outcome will be the average RNFL thickness at 6 months. Additional pre-specified statistical analyses will compare the difference in the mean RNFL thickness at 6 months in the affected eye between the IV methylprednisolone- and Acthar-treated groups, and the mean 6-month affected eye RNFL thicknesses adjusted for the baseline unaffected eye RNFL. The secondary outcome measure will examine the frequency of optic nerves with RNFL swelling between the IV methylprednisolone- and Acthar-treated groups at 1 and 3 months. A predefined exploratory outcome will compare the ganglion cell plus inner plexiform layer (GC+IPL) thickness at 6 months between treatment groups. Additional tertiary outcome will be the assessment of changes in fatigue, mood, visual function depression, and quality of life in patients with AON. Assessment will be completed by administration of the following questionnaires: Modified Fatigue Impact Scale, Multiple Sclerosis Quality of Life 54 Instrument, 25-item Visual Function Questionnaire with 10-item supplement, Beck's Depression Inventory. These questionnaires have been validated for the MS (AON) population. Descriptive and correlative analysis will be done at each visit time point to assess for QOL for this study population.


Condition or disease Intervention/treatment Phase
Multiple Sclerosis Drug: ACTHAR Gel (ACTH) Drug: IV methylprednisolone (steroids) Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis
Study Start Date : May 2013
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2021


Arm Intervention/treatment
Experimental: Acthar Gel (ACTH)
15 days of intramuscular (IM) or sub-cutaneous corticotropin (SQ) Acthar (ACTH).
Drug: ACTHAR Gel (ACTH)
15 days of daily injections
Other Name: ACTH

Active Comparator: IV methylprednisolone (steroids)
3 days of IV methylprednisolone (steroids) followed by 11 days of oral prednisone
Drug: IV methylprednisolone (steroids)
3 days of intravenous methylprednisolone followed by 11 days of oral taper
Other Name: methylprednisolone




Primary Outcome Measures :
  1. Retinal Nerve Fiber Layer (RNFL) thickness [ Time Frame: 6 months ]
    The primary outcome will be the average RNFL thickness at 6 months.


Secondary Outcome Measures :
  1. Frequency of RNFL swelling [ Time Frame: 1 and 3 months ]
    The secondary outcome measure will examine the frequency of optic nerves with RNFL swelling between the IV methylprednisolone- and Acthar-treated groups at 1 and 3 months.


Other Outcome Measures:
  1. Comparison of ganglion cell plus inner plexiform layer (GC+IPL) thickness at 6 months [ Time Frame: 6 months ]
    Exploratory outcome will compare the ganglion cell plus inner plexiform layer (GC+IPL) thickness at 6 months between treatment groups

  2. Assessment of changes in fatigue in patients with AON. [ Time Frame: Baseline, Month 1, 3, 6 ]
    Assessment will be completed by administration of the following questionnaire: Modified Fatigue Impact Scale. This questionnaire has been validated for the MS (AON) population. Descriptive and correlative analysis will be done at each visit time point to assess for QOL for this study population.

  3. Assessment in mood in patients with AON. [ Time Frame: Baseline, Month 1, 3, 6 ]
    Assessment will be completed by administration of the following questionnaire: Multiple Sclerosis Quality of Life 54 Instrument. This questionnaire has been validated for the MS (AON) population. Descriptive and correlative analysis will be done at each visit time point to assess for QOL for this study population.

  4. Assessment in visual function in patients with AON. [ Time Frame: Baseline, Month 1, 3, 6 ]
    Assessment will be completed by administration of the following questionnaires: 25-item Visual Function Questionnaire with 10-item supplement.

  5. Assessment in quality of life in patients in patients with AON. [ Time Frame: Baseline, Month 1, 3, 6 ]
    Assessment will be completed by administration of the following questionnaire: Beck's Depression Inventory.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. Ability to provide written informed consent before any study assessment is performed.
  2. Male and female patients aged between 18 and 55 years, inclusive.
  3. Diagnosis of clinically unilateral acute demyelinating optic neuritis (ADON)
  4. Clinical signs and symptoms of ADON starting within the 14 day prior to intended randomization (loss of vision, pain on movement, impairment of color vision).
  5. The qualifying episode of optic neuritis must be the first clinical episode of optic neuritis in the affected eye.
  6. Able to undergo treatment with intravenous methylprednisolone or Acthar gel.

Exclusion Criteria:

  1. Functionally or clinically relevant comorbidity of the affected eye (e.g., glaucoma, amblyopia, optic nerve hypoplasia, macular hole, macular edema, vitreomacular traction, uveitis, diabetes, optic neuritis, or other diseases of the optic nerve or a history thereof).
  2. Bilateral optic neuritis.
  3. Concurrent functionally or clinically relevant disturbances of the eye not affected by ADON.
  4. High clinical likelihood of a form of optic neuritis other than ADON (e.g., no pain on movement, no light perception, severe optic disk edema, atrophic optic disk, retinal exudates, or hemorrhages).
  5. Non-assessable OCT at screening.
  6. Refractive error greater than ±5 diopters or (pre-surgical value to be used for patients having undergone refractive surgery).
  7. Patients with an immune system disorder other than MS or ADON (e.g. rheumatoid arthritis, scleroderma, Sjogren's syndrome, Crohn's disease, ulcerative colitis, etc.) or with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug-induced immune deficiency). Diagnosis of neuromyelitis optica or MOG-IgG will not exclude a patient from the study but will be accounted for in the data analysis.
  8. Prior treatment with IVMP or Acthar gel within the past 30 days.
  9. Treatment with, mitoxantrone, cyclophosphamide, mycophenolate, azathioprine, or other non-approved agents for the treatment of relapsing forms of MS.
  10. Concurrent use of 4-aminopyridine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01838174


Contacts
Contact: Ruth Johnson, BS 303-724-7885 Ruth.Johnson@ucdenver.edu
Contact: Meghan Karlik 215-662-8094 Meghan.Karlik@uphs.upenn.edu

Locations
United States, Colorado
University of Colorado Denver Recruiting
Aurora, Colorado, United States, 80045
Contact: Ruth Johnson, BS    303-724-7885    Ruth.Johnson@ucdenver.edu   
Principal Investigator: Jeffrey Bennett, MD, PhD         
United States, Pennsylvania
University of Pennsylvania Scheie Eye Institute Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Meghan Karlik    215-662-8094    Meghan.Karlik@uphs.upenn.edu   
Principal Investigator: Kenneth S Shindler, MD, PhD         
Sponsors and Collaborators
University of Colorado, Denver
Mallinckrodt
University of Pennsylvania
Investigators
Principal Investigator: Jeffrey Bennett, MD, PhD University of Colorado, Denver
Principal Investigator: Kenneth Shindler, MD, PhD University of Pennsylvania Scheie Eye Institute

Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT01838174     History of Changes
Other Study ID Numbers: 13-0388
First Posted: April 23, 2013    Key Record Dates
Last Update Posted: October 3, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by University of Colorado, Denver:
Optic Neuritis

Additional relevant MeSH terms:
Multiple Sclerosis
Neuritis
Optic Neuritis
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Optic Nerve Diseases
Cranial Nerve Diseases
Eye Diseases
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone hemisuccinate
Prednisolone phosphate
Adrenocorticotropic Hormone
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones